Drug Trial Radar · NCT02125721
Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria
Last checked: Nov 19, 2026Latest source record: Aug 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Jun 2012
Primary completion
Dec 2017
Study completion Dec 2017
Sponsor
- Lead sponsor
- NYU Langone HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- First posted
- Apr 29, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of escalating doses of cystine biding thiol drugs, including tiopronin and d-penicillamine, on the urinary cystine capacity, which is a measure of the amount of cystine in the urine, in patients with cystinuria. The overall goal will be to help guide therapy and ultimately minimize unnecessary side effects caused by larger doses.
Conditions
- Cystinuria
Interventions
Tiopronin 1g per dayDrug
500mg PO BID x 7 days
Tiopronin 2g per dayDrug
1g PO BID x 7 days
Tiopronin 3g per dayDrug
1.5g PO BID x 7 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cystine CapacityTime frame: 4 weeks on assigned therapy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NYU Langone Medical Center
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.